Clinical Trials Logo

Antimetabolites, Antineoplastic clinical trials

View clinical trials related to Antimetabolites, Antineoplastic.

Filter by:
  • None
  • Page 1

NCT ID: NCT04365101 Active, not recruiting - Pneumonia Clinical Trials

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

CYNKCOVID
Start date: May 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

NCT ID: NCT04310592 Recruiting - Leukemia Clinical Trials

Natural Killer Cell (CYNK-001) Infusions in Adults With AML

CYNK001AML01
Start date: March 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

NCT ID: NCT01964430 Completed - Neoplasms Clinical Trials

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

apact
Start date: March 28, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.